Search Results for "dabigatran"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for dabigatran. Results 1 to 8 of 8 total matches.
See also: Pradax, Pradaxa

Table 3: Some Drug Interactions with DAAs for HCV Infection (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024  (Issue 1714)
levels Dabigatran Increased dabigatran serum concentrations Follow renal-adjusted dosing for dabigatran ...
View Table 3: Some Drug Interactions with DAAs for HCV Infection
Med Lett Drugs Ther. 2024 Oct 28;66(1714):e175   doi:10.58347/tml.2024.1714f |  Show IntroductionHide Introduction

Drugs for Treatment and Prevention of Venous Thromboembolism

   
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022  (Issue 1655)
therapy should be continued for at least 3 months.3 A DOAC (apixaban, dabigatran [Pradaxa], edoxaban ...
Anticoagulants are the drugs of choice for treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE). US guidelines for treatment of VTE were updated in 2020 and 2021.
Med Lett Drugs Ther. 2022 Jul 25;64(1655):113-20 |  Show IntroductionHide Introduction

Treatment of Atrial Fibrillation

   
The Medical Letter on Drugs and Therapeutics • Jan 08, 2024  (Issue 1693)
— The direct oral anticoagulants (DOACs) dabigatran (Pradaxa, and generics), rivaroxaban (Xarelto), apixaban ...
Atrial fibrillation (AF) is the most common arrhythmia in the world. Risk factor modification, anticoagulation, rhythm control, and rate control are the four pillars of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines on management of AF were updated recently.
Med Lett Drugs Ther. 2024 Jan 8;66(1693):1-8   doi:10.58347/tml.2024.1693a |  Show IntroductionHide Introduction

Comparison Table: Some Oral Anticoagulants for VTE (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022  (Issue 1655)
Interactions Comments Cost2 Direct Thrombin Inhibitor Dabigatran etexilate – Pradaxa (Boehringer Ingelheim ...
View the Comparison Table: Some Oral Anticoagulants for VTE
Med Lett Drugs Ther. 2022 Jul 25;64(1655):e122-4 |  Show IntroductionHide Introduction

Balfaxar: Another Four-Factor PCC for Warfarin Reversal

   
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024  (Issue 1696)
the anticoagulant effect of dabigatran (Pradaxa); whether PCCs can safely reverse the anticoagulant effect ...
Balfaxar (Octapharma), a human plasma-derived four-factor prothrombin complex concentrate (PCC), has been approved by the FDA for rapid reversal of warfarin anticoagulation in adults who require an urgent surgical/invasive procedure. It is the second four-factor PCC to become available in the US; Kcentra, which has been available since 2013, is approved for the same indication and for urgent reversal of warfarin anticoagulation in adults with acute major bleeding. Balfaxar is marketed in Canada and Europe as Octaplex.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):31-2   doi:10.58347/tml.2024.1696d |  Show IntroductionHide Introduction

Lipid-Lowering Drugs

   
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022  (Issue 1659)
are at increased risk for muscular adverse effects.10 In patients taking dabigatran etexilate (Pradaxa ...
Cholesterol management guidelines from the American College of Cardiology/American Heart Association Task Force were last published in 2019.
Med Lett Drugs Ther. 2022 Sep 19;64(1659):145-52 |  Show IntroductionHide Introduction

Drugs for Hepatitis C Virus Infection

   
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024  (Issue 1714)
., statins, cyclosporine, dabigatran, digoxin). Glecaprevir and pibrentasvir are substrates of P-gp ...
About 2.5 million persons in the US had hepatitis C between 2017 and 2020. Guidelines from the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) on management of hepatitis C virus (HCV) infection were updated in 2023.
Med Lett Drugs Ther. 2024 Oct 28;66(1714):169-74   doi:10.58347/tml.2024.1714a |  Show IntroductionHide Introduction

Comparison Table: Some Lipid-Lowering Drugs (online only)

   
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022  (Issue 1659)
increase the risk of major hemorrhage in patients taking dabigatran etexilate (Pradaxa); mechanism ...
View the Comparison Table: Some Lipid-Lowering Drugs
Med Lett Drugs Ther. 2022 Sep 19;64(1659):e152-6 |  Show IntroductionHide Introduction